BioCentury | Jan 5, 2004
Company News

Endo management update

Endo Pharmaceuticals Holdings Inc. (ENDP), Chadds Ford, Penn. Business: Neurology Hired: Stephen Andrzejewski as group VP of commercial business, formerly VP of new products at Schering-Plough Corp. 's Schering Laboratories division; Roland Gerritsen van der...
BioCentury | Apr 22, 2002
Company News

OxiGene board of directors update

OxiGene Inc. (OXGN; SSE:OXGN), Watertown, Mass. Business: Cancer Appointed: William Shiebler, CEO of Deutsche Bank Group's Americas for Deutsche Asset Management; he replaces Ron Pero, who departed WIR Staff cancer...
BioCentury | Oct 30, 2000
Company News

OxiGene management update

OxiGene Inc. (OXGN; SSE:OXGN), Boston, Mass. Business: Cancer Hired: Frederick Driscoll as president, formerly SVP of finance and operations at Collagenesis Corp. Retired: Ron Pero as CSO WIR Staff cancer...
BioCentury | May 15, 1995
Clinical News

OXiGENEInc preclinical data

OXGN (New York) said the number of vomiting incidents was lowered in a 15-dog, cross-over study using cisplatin as the emetic, but the data did not achieve statistical significance (p=0.06 compared to standard anti-emetics). The...
Items per page:
1 - 4 of 4
BioCentury | Jan 5, 2004
Company News

Endo management update

Endo Pharmaceuticals Holdings Inc. (ENDP), Chadds Ford, Penn. Business: Neurology Hired: Stephen Andrzejewski as group VP of commercial business, formerly VP of new products at Schering-Plough Corp. 's Schering Laboratories division; Roland Gerritsen van der...
BioCentury | Apr 22, 2002
Company News

OxiGene board of directors update

OxiGene Inc. (OXGN; SSE:OXGN), Watertown, Mass. Business: Cancer Appointed: William Shiebler, CEO of Deutsche Bank Group's Americas for Deutsche Asset Management; he replaces Ron Pero, who departed WIR Staff cancer...
BioCentury | Oct 30, 2000
Company News

OxiGene management update

OxiGene Inc. (OXGN; SSE:OXGN), Boston, Mass. Business: Cancer Hired: Frederick Driscoll as president, formerly SVP of finance and operations at Collagenesis Corp. Retired: Ron Pero as CSO WIR Staff cancer...
BioCentury | May 15, 1995
Clinical News

OXiGENEInc preclinical data

OXGN (New York) said the number of vomiting incidents was lowered in a 15-dog, cross-over study using cisplatin as the emetic, but the data did not achieve statistical significance (p=0.06 compared to standard anti-emetics). The...
Items per page:
1 - 4 of 4